Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1744 CL Respimat dose-schedule crossover study in COPD
2008-006334-10Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Forced expiratory volume in one second (FEV1). Started Nov 2008; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-006334-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006334-10.